Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b, Multicenter, Open-Label Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed WHO Grade IV Malignant Glioma

NCT02903069 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02903069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02903069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b, Multicenter, Open-Label Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed WHO Grade IV Malignant Glioma
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Completed
Start date
August 17, 2016
Completion date
January 25, 2021
Enrollment
66 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, malignant glioma